EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+4.24%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.13B
AUM Growth
+$3.13B
(+10%)
Cap. Flow
+$493M
Cap. Flow
% of AUM
15.74%
Top 10 Holdings %
Top 10 Hldgs %
65.45%
Holding
90
New
19
Increased
10
Reduced
3
Closed
13
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$191M |
| 2 |
CRISPR Therapeutics
CRSP
|
$81.7M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$71.4M |
| 4 |
TSVT
2seventy bio
TSVT
|
$49.1M |
| 5 |
Atea Pharmaceuticals
AVIR
|
$48.1M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$82.1M |
| 2 |
Shattuck Labs
STTK
|
$75.6M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$25.2M |
| 4 |
Nurix Therapeutics
NRIX
|
$23.7M |
| 5 |
BLUE
bluebird bio
BLUE
|
$15.3M |
Sector Composition
| 1 | Healthcare | 99.03% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $557M | 17.76% | 11,284,280 | – | – |
|
2
AnaptysBio
ANAB
$569M
| $261M | 8.33% | 7,521,024 | – | – |
|
3
Arcus Biosciences
RCUS
$1.13B
| $224M | 7.12% | 5,523,358 +400,999 | +8% | +$16.2M |
|
4
Xencor
XNCR
$580M
| $197M | 6.27% | 4,906,106 | – | – |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $191M | 6.08% | +4,033,882 | New | +$191M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $187M | 5.97% | 3,951,566 | – | – |
|
7
Galapagos
GLPG
$2.07B
| $123M | 3.91% | 2,224,403 +665,654 | +43% | +$36.7M |
|
8
Nuvation Bio
NUVB
$1.02B
| $118M | 3.76% | 13,896,543 +185,026 | +1% | +$1.57M |
|
9
Alector
ALEC
$238M
| $103M | 3.29% | 4,994,970 | – | – |
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $90.3M | 2.88% | 2,639,706 +1,195,906 | +83% | +$40.9M |
|
|
11
CRISPR Therapeutics
CRSP
$4.71B
| $81.7M | 2.6% | +1,077,483 | New | +$81.7M |
|
|
GRTS
12
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $77.3M | 2.46% | 6,012,232 +451,484 | +8% | +$5.81M |
|
|
13
Acadia Pharmaceuticals
ACAD
$4.38B
| $71.4M | 2.28% | +3,060,593 | New | +$71.4M |
|
14
Avidity Biosciences
RNA
$5.99B
| $65.6M | 2.09% | 2,759,505 | – | – |
|
15
iTeos Therapeutics
ITOS
| $60.7M | 1.93% | 1,303,157 | – | – |
|
16
Relay Therapeutics
RLAY
$619M
| $54.6M | 1.74% | 1,779,084 +393,808 | +28% | +$12.1M |
|
17
Kura Oncology
KURA
$686M
| $52.1M | 1.66% | 3,724,437 | – | – |
|
18
Oric Pharmaceuticals
ORIC
$994M
| $51M | 1.63% | 3,468,944 | – | – |
|
|
TSVT
19
DELISTED
2seventy bio
TSVT
| $49.1M | 1.57% | +1,917,063 | New | +$49.1M |
|
|
20
Atea Pharmaceuticals
AVIR
$267M
| $48.1M | 1.53% | +5,376,134 | New | +$48.1M |
|
21
Design Therapeutics
DSGN
$315M
| $46.1M | 1.47% | 2,152,997 +289,899 | +16% | +$6.21M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $40M | 1.28% | +940,636 | New | +$40M |
|
23
Janux Therapeutics
JANX
$1.37B
| $27.9M | 0.89% | 1,411,975 | – | – |
|
|
PRDS
24
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $26.1M | 0.83% | 1,597,139 +1,226,125 | +330% | +$20.1M |
|
25
Ventyx Biosciences
VTYX
$171M
| $25.8M | 0.82% | +1,300,000 | New | +$25.8M |
|